MedTrace Logo

LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

NCT03244020 · Status: ENROLLING_BY_INVITATION · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2868

Last updated 2025-10-03

No results posted yet for this study

Summary

Aspirin and low molecular weight heparin (LMWH) are both commonly employed pharmacologic methods of venous thromboembolism (VTE) prophylaxis after orthopaedic surgery. Data comparing these two methods of VTE prophylaxis in patients undergoing pelvic/lower extremity orthopaedic surgery for malignancy are lacking, however, as compared to the data and guidelines present for VTE chemoprophylaxis after joint arthroplasty and hip fracture surgery. In this clinical trial, our specific aim is to compare the post operative incidence of VTE between patients receiving aspirin and LMWH after pelvic/lower extremity orthopaedic oncology procedures.

Conditions

  • Sarcoma
  • Soft Tissue Sarcoma
  • Bone Sarcoma
  • Bone Metastases
  • Venous Thromboembolism
  • Hematoma
  • Anticoagulant-induced Bleeding

Interventions

DRUG

Aspirin 325mg

Aspirin 325 mg by mouth once daily

DRUG

Enoxaparin 40Mg/0.4mL Prefilled Syringe

Enoxaparin 40 mg subcutaneous injection once daily

Sponsors & Collaborators

  • Johns Hopkins University

    collaborator OTHER

  • University of Missouri-Columbia

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Santiago A Lozano-Calderon, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-16
Primary Completion
2027-12-31
Completion
2028-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03244020 on ClinicalTrials.gov